OGEN Oragenics Inc
Price (delayed)
$0.1999
Market cap
$4.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.6
Enterprise value
$3.76M
Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against
Highlights
OGEN's EPS has surged by 83% year-on-year and by 77% since the previous quarter
Oragenics's net income has increased by 49% YoY and by 47% from the previous quarter
Oragenics's equity has plunged by 107% from the previous quarter and by 107% YoY
Oragenics's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of OGEN
Market
Valuations
Earnings
Shares outstanding
21.48M
Market cap
$4.29M
Enterprise value
$3.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$10.56M
Net income
-$10.57M
EBIT
-$10.54M
EBITDA
-$10.54M
Free cash flow
-$8.6M
Per share
Balance sheet
Liquidity
EPS
-$1.6
EPS diluted
-$1.6
Free cash flow per share
-$1.3
Book value per share
-$0.02
Revenue per share
$0
TBVPS
$0.22
Total assets
$1.47M
Total liabilities
$1.68M
Debt
$328,528
Equity
-$211,885
Working capital
-$211,885
Debt to equity
-1.55
Current ratio
0.87
Quick ratio
0.51
Net debt/EBITDA
0.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-327.2%
Return on equity
-620.1%
Return on invested capital
-11,624.3%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OGEN stock price
How has the Oragenics stock price performed over time
Intraday
-5.84%
1 week
-18.81%
1 month
-31.07%
1 year
-86.4%
YTD
-45.87%
QTD
-4.81%
Financial performance
How have Oragenics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.56M
Net income
-$10.57M
Gross margin
N/A
Net margin
N/A
Oragenics's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
OGEN's operating income is up by 49% year-on-year and by 47% since the previous quarter
Oragenics's net income has increased by 49% YoY and by 47% from the previous quarter
Growth
What is Oragenics's growth rate over time
Valuation
What is Oragenics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OGEN's EPS has surged by 83% year-on-year and by 77% since the previous quarter
Oragenics's equity has plunged by 107% from the previous quarter and by 107% YoY
Oragenics's revenue has shrunk by 100% YoY
Efficiency
How efficient is Oragenics business performance
OGEN's ROE has plunged by 104% YoY but it is up by 21% from the previous quarter
The company's return on invested capital has shrunk by 63% QoQ
OGEN's ROA is up by 33% since the previous quarter but it is down by 33% year-on-year
Dividends
What is OGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OGEN.
Financial health
How did Oragenics financials performed over time
The total assets is 13% less than the total liabilities
The company's quick ratio has shrunk by 74% YoY and by 66% QoQ
The total assets has plunged by 72% from the previous quarter and by 70% YoY
Oragenics's equity has plunged by 107% from the previous quarter and by 107% YoY
The debt has declined by 37% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.